Table 1 Patient characteristics and univariate Cox regression.
Characteristic | Ā | Group A | Group B | ||||
|---|---|---|---|---|---|---|---|
n (%) | 1-year OS (%) | Median (moths) | n (%) | 1-year OS (%) | Median (moths) | ||
Gender | Male | 70 (49.3) | 43.3 | 9.6 | 25 (47.2%) | 59.0 | 15.8 |
Female | 72 (50.7) | 49.9 | 12.0 | 28 (53.8%) | 73.3 | 20.7 | |
Age (year) | <50āy | 36 (25.4) | 50.6 | 15.2 | 13 (24.5%) | 60.6 | 15.3 |
50ā59āy | 49 (34.5) | 48.8 | 11.7 | 16 (30.2%) | 73.1 | 20.7 | |
ā„60āy | 57 (40.1) | 42.4 | 9.0 | 24 (45.3%) | 66.2 | 26.0 | |
Smoking | No | 87 (61.3) | 48.8 | 12.0 | 34 (64.2%) | 75.0 | 24.0 |
Yes | 55 (38.7) | 42.8 | 9.0 | 19 (35.8%) | 51.1 | 15.8 | |
CEA | Normal | 68 (47.9) | 48.7 | 11.4 | 24 (45.3%) | 60.6 | 15.0 |
Abnormal | 74 (52.1) | 44.7 | 10.1 | 29 (54.7%) | 71.5 | 26.0 | |
CA199 | Normal | 103 (72.5) | 46.0 | 10.2 | 46 (86.8%) | 66.8 | 20.0 |
Abnormal | 39 (27.5) | 47.6 | 12.0 | 7 (13.2%) | 68.6 | 20.0 | |
SCC | Normal | 137 (96.5) | 47.3 | 11.4 | 49 (92.5%) | 64.4 | 17.0 |
Abnormal | 5 (3.5) | 26.7 | 12.0 | 4 (7.5%) | NA | 24.0 | |
NSE | Normal | 135 (95.1) | 46.7 | 11.4 | 51 (96.2%) | 67.5 | 20.0 |
Abnormal | 7 (4.9) | 42.9 | 6.9 | 2 (3.8%) | 50.0 | 1.8 | |
Primary | Controlled | 19 (13.4) | 62.0 | 15.2 | 34 (64.2%) | 67.8 | 17.0 |
tumor | Uncontrolled | 123 (86.6) | 44.7 | 10.1 | 19 (35.8%) | 64.8 | 24.0 |
Extracranial | Yes | 110 (77.5) | 44.6 | 9.7 | 9 (17.0%) | 77.8 | 27.0 |
metastases | No | 32 (22.5) | 53.8 | 12.5 | 44 (83.0%) | 64.0 | 20.0 |
NoBM | 1 | 51 (35.9) | 55.0 | 13.3 | 18 (34.0%) | 81.0 | NA |
2ā3 | 41 (28.9) | 39.9 | 9.7 | 19 (35.8%) | 51.6 | 26.0 | |
>3 | 50 (35.2) | 43.5 | 9.3 | 16 (30.2%) | 68.2 | 17.0 | |
ProGRP | Normal | 141 (99.3) | 47.0 | 11.4 | 51 (96.2%) | 65.4 | 20.0 |
Abnormal | 1 (0.7) | 0.0 | 6.9 | 2 (3.8%) | 50.0 | 17.0 | |
Treatment | No treatment | 17 (12.0) | 17.6 | 4.4 | 1 (1.9%) | NA | NA |
Chemotherapy | 42 (29.6) | 50.5 | 15.5 | 26 (49.0%) | 49.7 | 11.3 | |
Radiotherapy | 28 (19.7) | 59.2 | 14.4 | 1 (1.9%) | NA | NA | |
Combined | 39 (27.5) | 48.2 | 11.4 | 24 (45.3%) | 83.1 | 26.0 | |
TKI alone | 16 (11.3) | 53.0 | 10.1 | 1 (1.9%) | NA | NA | |
EGFR | wt | 73 (51.4) | 42.3* | 9.7 | 26 (49.1%) | 51.0 | 15.8* |
mut | 69 (48.6) | 51.1 | 12.5 | 27 (50.9%) | 80.7 | 30.0 | |
EGFR-20 | wt | 76 (53.5) | 42.0* | 9.6 | 26 (49.1%) | 51.0 | 15.8* |
mut | 66 (46.5) | 51.8 | 12.5 | 27 (50.9%) | 80.7 | 30.0 | |
Cy211 | Normal | 45 (31.7) | 62.3* | 15.5 | 34 (64.2%) | 70.9 | 17.0 |
Abnormal | 97 (68.3) | 39.8 | 9.2 | 19 (35.8%) | 60.5 | 24.0 | |
CA125 | Normal | 74 (52.1) | 57.6** | 14.8 | 37 (69.8%) | 61.8 | 15.8 |
Abnormal | 68 (47.9) | 34.4 | 8.6 | 16 (30.2%) | 79.1 | 24.0 | |
TKI therapy | No | 83 (58.5) | 38.1* | 8.6 | 28 (52.8%) | 51.3 | 15.8 |
in wt pt | 12 (8.5) | 65.6 | 15.2 | 6 (11.3%) | 50.0 | 7.0 | |
In mut pt | 47 (33.1) | 57.3 | 16.3 | 19 (35.8%) | 89.5 | 30.0 | |
BM | Already | 98 (69.0) | 48.7* | 11.8 | 6 (11.3%) | NA* | NA |
Developed | 44 (31.0) | 42.7 | 8.0 | 47 (88.7%) | 62.0 | 15.8 | |
KPS | <70 | 40 (28.2) | 7.8** | 3.2 | 12 (22.6%) | 0.00** | 4.0 |
70ā80 | 86 (60.6) | 53.8 | 13.3 | 31 (58.5%) | 91.5 | 26.0 | |
90ā100 | 16 (11.3) | 93.8 | 33.4 | 10 (18.9%) | 70.0 | 24.0 | |
modified-RPA | Classes I | 1 (0.7) | NA** | NA | 13 (24.5%) | 91.7** | 20.0 |
Classes II | 101 (71.1) | 60.3 | 15.2 | 29 (54.7%) | 79.7 | 26.0 | |
Classes III | 40 (28.2) | 7.8 | 3.2 | 11 (20.8%) | 0.0 | 4.0 | |
lung-GPA | 0ā1 | 52 (36.6) | 27.4** | 6.0 | 6 (11.3%) | 66.7 | 17.0 |
1.5ā2.5 | 77 (54.2) | 52.9 | 12.5 | 37 (69.8%) | 57.5 | 15.0 | |
3 | 9 (6.3) | 77.8 | 16.4 | 6 (11.3%) | 100.0 | NA | |
>3.5 | 4 (2.8) | 66.7 | 33.4 | 4 (7.5%) | 100.0 | 20.0 | |
